IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Merial Limited v Bayer Intellectual Property GmbH [2016] APO 17
Patent Application: 2007341648
Title:Combination product for controlling parasites on animals
Patent Applicant: Bayer Intellectual Property GmbH
Opponent: Merial Limited
Delegate: Dr M-A. Fam
Decision Date: 1 April 2016
Hearing Date: 19 February 2016, in Canberra
Catchwords: PATENTS – section 59 – opposition to the grant of a patent – grounds of novelty and inventive step considered – novelty – citation does not disclose all the features of the claims – inventive step – determining the problem requires consideration of the common general knowledge and subsection 7(3) information – problem addressed is the provision of a topical ectoparasiticidal formulation that has a broad spectrum of activity, is safe to use on the target animal and reduces penetration of N-arylpyrazoles into the circulation – evidence does not establish that formulation of two active ingredients and three other components is a matter of routine – opposition fails
Representation: Patent applicant: Mr Julian Cooke of counsel instructed by Dr Mathew Lucas and Dr Althea Tsang of Davies Collison Cave
Opponent: Mr Tom Cordiner of counsel instructed by Dr Marcus Caulfield and Dr Toby Thompson of FB Rice
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2007341648
Title:Combination product for controlling parasites on animals
Patent Applicant: Bayer Intellectual Property GmbH
Date of Decision: 1 April 2016
DECISION
The opposition fails on all grounds. Subject to appeal, I direct the application proceed to grant. Costs according to Schedule 8 are awarded against Merial Limited.
REASONS FOR DECISION
1. Background
The present application was filed by Bayer Healthcare AG on 14 December 2007. Bayer Healthcare AG subsequently changed its name to Bayer Animal Health GmbH and the latter assigned its rights to Bayer Intellectual Property GmbH (Bayer). Following examination, the application was advertised accepted on 5 June 2014.
A notice of opposition was filed by Merial Limited (Merial) on 5 September 2014. A hearing was held in Canberra on 19 February 2016. Bayer was represented by Mr Julian Cooke of counsel instructed by Dr Mathew Lucas and Dr Althea Tsang of Davies Collison Cave. Merial was represented by Mr Tom Cordiner of counsel instructed by Dr Marcus Caulfield and Dr Toby Thompson of FB Rice.
The request for examination in relation to the application was filed on 22 September 2011. Consequently, substantive amendments of the Patents Act 1990 brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 do not apply to the present application. This includes the amendment to subsection 60 (3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition exists. Any subsequent references to sections of the Patents Act relate to the Patents Act 1990 prior to amendment by the Raising the Bar Act. A similar qualification applies to references to the Patents Regulations 1991.
It is noted that the parties were heard in relation to the opposition to the…
Keep reading for free
Create a free CaseChat account to read Merial Limited v Bayer Intellectual Property GmbH and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2016] APO 17
- Decision Date
CaseChat Overview and Summary
Background
Background to the litigation
The patent application was filed by Bayer Healthcare AG on 14 December 2007, which was later assigned to Bayer Intellectual Property GmbH. After examination, the application was accepted on 5 June 2014. Merial Limited filed a notice of opposition on 5 September 2014. The opposition was heard in Canberra on 19 February 2016, with Bayer represented by Mr Julian Cooke and Merial represented by Mr Tom Cordiner. The opposition was based on several grounds, but only novelty and inventive step were pressed at the hearing. The decision on the opposition was issued on 1 April 2016 by Dr M-A. Fam, who found that the opposition failed on all grounds.
Decision
Reasons for decision
1. Whether the claimed invention is novel in view of the prior art.
2. Whether the claimed invention involves an inventive step in light of the common general knowledge and the prior art.
3. Whether the claimed invention involves a manner of manufacture that is clear, fair, and sufficient.
Held
1. The opposition by Merial Limited against Bayer Intellectual Property GmbH's patent application 2007341648 fails on all grounds.
2. Subject to appeal, the application is directed to proceed to grant.
3. Costs are awarded to Bayer Intellectual Property GmbH against Merial Limited.
Ratio Decidendi
Legal Principle Established
The decision of Dr M-A. Fam, as the Delegate of the Commissioner of Patents, focused on the issues of novelty, inventive step, and manner of manufacture. The court considered various prior art documents and expert opinions to determine whether the claimed invention was novel and involved an inventive step. The decision found that the claimed invention was novel and did not lack an inventive step either in light of the common general knowledge or the prior art.
The court began by assessing whether the claimed invention was novel. The decision noted that for an invention to lack novelty, the prior art must disclose all the essential features of the invention. The court found that the prior art documents did not disclose a composition comprising an N-arylpyrazole, a pyrethroid, an aliphatic cyclic carbonate, an aliphatic cyclic or acyclic polyether, and an ester of a dihydric or trihydric alcohol with organic fatty acids. Therefore, the claims were found to be novel.
Next, the court turned to the issue of whether the claimed invention involved an inventive step. The decision considered the problem that the specification sought to address, which was the provision of a topical ectoparasiticidal formulation that had a broad spectrum of activity, was safe to use on the target animal, and reduced penetration of N-arylpyrazoles into the circulation. The court evaluated whether it would have been obvious for a person skilled in the art to combine the claimed ingredients to solve this problem. The evidence presented by the declarants indicated that combining the ingredients was not a straightforward process and that improper formulation could result in crystallization of fipronil and loss of efficacy. Therefore, the court found that the claims involved an inventive step.
The court also considered the manner of manufacture, concluding that the claims were clear, fair, and sufficient. The decision noted that the claims were directed to a composition per se and defined the composition in a manner that was suitable for controlling parasites on animals. The specification provided sufficient details to enable a person skilled in the art to reproduce the claimed invention.
In summary, the ratio decidendi of this decision is that the claimed invention in Bayer Intellectual Property GmbH's patent application 2007341648 is both novel and involves an inventive step, and the claims are clear, fair, and sufficient. Therefore, the opposition by Merial Limited fails on all grounds, and the application is directed to proceed to grant.